เอกสารอ้างอิง
[1.] McVary KT. Clinical manifestations and diagnostic evaluation of benign prostatic hyperplasia. Up-to-Date [database on the Internet]. Waltham (MA): UpToDate; 2020 [cited 2021 August 31]. Available from: http://www. uptodate.com.
[2.] McVary KT. Medical treatment of benign prostatic hyperplasia. Up-to-Date [database on the Internet]. Waltham (MA): UpToDate; 2020 [cited 2021 August 31]. Available from: http://www. uptodate.com.
[3.] Lerner LB, McVary, KT, Barry MJ et al: Management of lower urinary tract symptoms attributed to benign prostatic hyperplasia: AUA Guideline part I, initial work-up and medical management. J Urol 2021; https://doi.org/10.1097 /JU.000000000000 2183.
[4.] Doxazosin. In: Lexi-drugs online [database on the Internet]. Hudson (OH): Lexicomp, Inc.; 2021 [updated 28 August 2021; cited 31 August 2021]. Available from: http://online. lexi.com.
[5.] Kirby RS, Roehrborn C, Boyle P, et al. Efficacy and tolerability of doxazosin and finasteride, alone or in combination, in treatment of symptomatic benign prostatic hyperplasia: the Prospective European Doxazosin and Combination Therapy (PREDICT) trial. Urology. 2003;61(1):119-126. doi:10.1016 /s0090-4295(02)02114-3.
[6.] Rahardjo D, Soebadi DM, Sugandi S, Birowo P, Djati W, Wahyudi I. Efficacy and safety of tamsulosin hydrochloride compared to doxazosin in the treatment of Indonesian patients with lower urinary tract symptoms due to benign prostatic hyperplasia. Int J Urol. 2006;13(11):1405-1409. doi:10.1111/j.1442-2042.2006.01590.x.